Skip to main content

Table 1 Descriptive analysis of different DAA treatment regimens received by patients in group I

From: Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

HCV treatment

Number

Percent

SOF/DAC

1

2.0

SOF/DAC/RBV

30

60.0

SOF/LED

5

10.0

SOF/LED/RBV

1

2.0

SOF/RBV

9

18.0

SOF/SIM

4

8.0

HCV treatment (weeks)

 Min.–Max.

12.0–24.0

 Mean ± SD

14.64 ± 5.02

 Median

12.0

PCR after TTT

 SVR

42

84.0

 Relapser

8

16.0

  1. SOF sofosbuvir, LED ledipasvir, RBV ribavirin, SIM simeprevir, DAC daclatasvir, PCR polymerase chain reaction, SVR sustained virological response